VJHemOnc Podcast cover image

Highlights from iwMyeloma 2025: trial updates and practical considerations

VJHemOnc Podcast

00:00

Advancements in Myeloma Treatment

This chapter explores the pivotal advancements in myeloma treatment, emphasizing the role of Minimal Residual Disease (MRD) as a key endpoint for drug approval. It highlights the integration of new therapies like bispecific antibodies and CAR T-cell therapy, along with the importance of collaboration between academic institutions and community oncologists. Personal patient stories illustrate the transformative potential of these treatments, showcasing the need for adaptive strategies in managing care and improving outcomes.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app